Advanced search
Start date
Betweenand
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy

Full text
Author(s):
Ildefonso Alves da Silva Junior [1] ; Luciana Nogueira de Sousa Andrade [2] ; Sonia Jancar [3] ; Roger Chammas [4]
Total Authors: 4
Affiliation:
[1] Laboratorio de Imunofarmacologia. Instituto de Ciencias Biomedicas, Universidade de Sao Paulo. Departamento de Imunologia - Brasil
[2] Universidade de Sao Paulo. Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina. Laboratorio de Oncologia Experimental, Centro de Investigacao Translacional em Oncologia - Brasil
[3] Laboratorio de Imunofarmacologia. Instituto de Ciencias Biomedicas, Universidade de Sao Paulo. Departamento de Imunologia - Brasil
[4] Universidade de Sao Paulo. Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina. Laboratorio de Oncologia Experimental, Centro de Investigacao Translacional em Oncologia - Brasil
Total Affiliations: 4
Document type: Journal article
Source: Clinics; v. 73, 2018-10-11.
Abstract

Platelet activating factor is a lipid mediator of inflammation, and in recent decades, it has emerged as an important factor in tumor outcomes. Platelet activating factor acts by specific binding to its receptor, which is present in both tumor cells and cells that infiltrate tumors. Pro-tumorigenic effects of platelet activating factor receptor in tumors includes promotion of tumor cell proliferation, production of survival signals, migration of vascular cells and formation of new vessels and stimulation of dendritic cells and macrophages suppressor phenotype. In experimental models, blocking of platelet activating factor receptor reduced tumor growth and increased animal survival. During chemotherapy and radiotherapy, tumor cells that survive treatment undergo accelerated proliferation, a phenomenon known as tumor cell repopulation. Work from our group and others showed that these treatments induce overproduction of platelet activating factor-like molecules and increase expression of its receptor in tumor cells. In this scenario, antagonists of platelet activating factor markedly reduced tumor repopulation. Here, we note that combining chemo- and radiotherapy with platelet activating factor antagonists could be a promising strategy for cancer treatment. (AU)

FAPESP's process: 13/15719-0 - Association of receptors for lipid mediators with PRRs in macrophages and dendritic cells
Grantee:Sônia Jancar
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 15/22814-5 - Cancer and heart: new paradigms of diagnosis and treatment
Grantee:Carlos Eduardo Negrão
Support Opportunities: Research Projects - Thematic Grants